138 related articles for article (PubMed ID: 36238987)
1. Spatial-Temporal Trends in Ovarian Cancer Outcomes in California.
Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36238987
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment.
Villanueva C; Chang J; Bartell SM; Ziogas A; Bristow R; Vieira VM
J Natl Compr Canc Netw; 2019 Nov; 17(11):1318-1329. PubMed ID: 31693984
[TBL] [Abstract][Full Text] [Related]
3. Spatial analysis of advanced-stage ovarian cancer mortality in California.
Bristow RE; Chang J; Ziogas A; Gillen DL; Bai L; Vieira VM
Am J Obstet Gynecol; 2015 Jul; 213(1):43.e1-43.e8. PubMed ID: 25644440
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996-2014.
Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
Cancer Epidemiol; 2020 Dec; 69():101825. PubMed ID: 33022472
[TBL] [Abstract][Full Text] [Related]
5. Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California.
Vieira VM; Villanueva C; Chang J; Ziogas A; Bristow RE
Environ Res; 2017 Jul; 156():388-393. PubMed ID: 28395243
[TBL] [Abstract][Full Text] [Related]
6. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
[TBL] [Abstract][Full Text] [Related]
7. A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
Bristow RE; Chang J; Villanueva C; Ziogas A; Vieira VM
Obstet Gynecol; 2020 Feb; 135(2):328-339. PubMed ID: 31923082
[TBL] [Abstract][Full Text] [Related]
8. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.
Hodeib M; Chang J; Liu F; Ziogas A; Dilley S; Randall LM; Anton-Culver H; Bristow RE
Gynecol Oncol; 2015 Jul; 138(1):121-7. PubMed ID: 25913132
[TBL] [Abstract][Full Text] [Related]
9. Use of oral contraceptives and risk of breast cancer in young women.
Ursin G; Ross RK; Sullivan-Halley J; Hanisch R; Henderson B; Bernstein L
Breast Cancer Res Treat; 1998 Jul; 50(2):175-84. PubMed ID: 9822222
[TBL] [Abstract][Full Text] [Related]
10. Ambient air pollution and ovarian cancer survival in California.
Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
Gynecol Oncol; 2021 Oct; 163(1):155-161. PubMed ID: 34330535
[TBL] [Abstract][Full Text] [Related]
11. Pre-diagnosis fiber : carbohydrate intake ratio and mortality of ovarian cancer: results from a prospective cohort study.
Liu FH; Du ZD; Li XY; Wei YF; Wen ZY; Yan S; Sun ML; Qin X; Gao S; Gong TT; Wu QJ
Food Funct; 2022 Oct; 13(19):10046-10054. PubMed ID: 36093635
[No Abstract] [Full Text] [Related]
12. Epithelial ovarian cancer mortality among Hispanic women: Sub-ethnic disparities and survival trend across time: An analysis of SEER 1992-2013.
Chen C; Markossian TW; Silva A; Tarasenko YN
Cancer Epidemiol; 2018 Feb; 52():134-141. PubMed ID: 29306788
[TBL] [Abstract][Full Text] [Related]
13. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
14. Trends in Cancer Survival by Health Insurance Status in California From 1997 to 2014.
Ellis L; Canchola AJ; Spiegel D; Ladabaum U; Haile R; Gomez SL
JAMA Oncol; 2018 Mar; 4(3):317-323. PubMed ID: 29192307
[TBL] [Abstract][Full Text] [Related]
15. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease.
Bristow RE; Chang J; Ziogas A; Randall LM; Anton-Culver H
Gynecol Oncol; 2014 Feb; 132(2):403-10. PubMed ID: 24361578
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer and oral contraceptive use in Asian-American women.
Ursin G; Wu AH; Hoover RN; West DW; Nomura AM; Kolonel LN; Pike MC; Ziegler RG
Am J Epidemiol; 1999 Sep; 150(6):561-7. PubMed ID: 10489994
[TBL] [Abstract][Full Text] [Related]
17. Health Care Utilization Prior to Ovarian Cancer Diagnosis in Publicly Insured Individuals in New York State.
Gates Kuliszewski M; Boscoe FP; Wagner VL; Schymura MJ
J Registry Manag; 2021; 48(3):126-137. PubMed ID: 35413730
[TBL] [Abstract][Full Text] [Related]
18. The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study.
O'Malley CD; Shema SJ; Cress RD; Bauer K; Kahn AR; Schymura MJ; Wike JM; Stewart SL
J Womens Health (Larchmt); 2012 Sep; 21(9):887-94. PubMed ID: 22816528
[TBL] [Abstract][Full Text] [Related]
19. Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer.
Mukherjee A; Shammas N; Xu L; Cannavale KL; Gilfillan AD; Szamreta EA; Monberg M; Hodeib M; Chao CR
Front Oncol; 2024; 14():1290719. PubMed ID: 38601762
[TBL] [Abstract][Full Text] [Related]
20. Survival in Advanced Epithelial Ovarian Cancer Associated with Cardiovascular Comorbidities and Type 2 Diabetes Mellitus.
Slavchev S; Kornovski Y; Yordanov A; Ivanova Y; Kostov S; Slavcheva S
Curr Oncol; 2021 Sep; 28(5):3668-3682. PubMed ID: 34590605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
